The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the rationale and results of TakeAim Leukemia, a Phase I/IIa dose escalation and cohort expansion study evaluating the safety and clinical activity of the IRAK4 inhibitor emavusertib alone or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (NCT04278768). Overall, the agent showed a promising activity in this patient population, especially in patients with splicing mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
